Anlikang’s innovative drug ALK-N001 for injection clinical trial application accepted
February 22, 2025
Source: drugdu
32
On the evening of February 18, Zhejiang Anlikang Pharmaceutical Co., Ltd. issued an announcement stating that the company received the "Acceptance Notice" for the registration of domestically produced drug clinical trials for ALK-N001 for injection issued by the National Medical Products Administration.
According to reports, ALK-N001 for injection is a globally innovative tumor microenvironment-activated small molecule conjugate drug. Anlikang has obtained the rights to develop the drug in the licensed area (mainland China, Hong Kong Special Administrative Region, Macao Special Administrative Region, and Taiwan Province, China) through licensing. Preclinical study results show that the above-mentioned drug has a significant inhibitory effect on tumors in a variety of different tumor models and has good safety. It is a highly innovative and potential small molecule conjugate anti-tumor drug, which is expected to provide new treatment options for patients with advanced solid tumors.
https://finance.eastmoney.com/a/202502183322572549.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- First Pharmaceutical plans to increase the guarantee limit for its loss making subsidiary February 22, 2025
- supports the introduction of original drugs for domestic production; National Healthcare Security Administration February 22, 2025
- Two innovative medical devices have recently been approved February 22, 2025
- Urban cultural tourism and industrial development are gradually achieving two-way empowerment February 22, 2025
- Reaching $1.2 billion in overseas authorization, the old brand Shijiazhuang Pharmaceutical, which bets on innovative drugs, ushered in the harvest period February 22, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
